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Omega-6 to omega-3 polyunsaturated fatty acid ratio
and subsequent mood disorders in young people with
at-risk mental states: a 7-year longitudinal study
ME Berger1,2,3, S Smesny4, S-W Kim5, CG Davey3, S Rice3, Z Sarnyai1,2, M Schlögelhofer6, MR Schäfer3, M Berk3,7,8,9, PD McGorry3 and
GP Amminger3,6
While cross-sectional studies suggest that patients with mood disorders have a higher ratio of omega-6 to omega-3
polyunsaturated fatty acids (PUFAs) and lower levels of omega-3 PUFAs, it is unknown if a high n-6/3 ratio indicates vulnerability for
depression. We tested this hypothesis in a 7-year follow-up study of young individuals with an ultra-high risk (UHR) phenotype. We
conducted a secondary analysis of the Vienna omega-3 study, a longitudinal study of omega-3 PUFAs in individuals at UHR for
psychosis (n= 69). Levels of n-6 and n-3 PUFAs were measured in the phosphatidylethanolamine fraction of erythrocyte membranes
at intake into the study. Mood disorder diagnosis was ascertained with the Structured Clinical Interview for DSM-IV-TR and
confirmed by review of medical records and interviews of caregivers. A higher n-6/3 PUFA ratio at baseline predicted mood
disorders in UHR individuals over a 7-year (median) follow-up (odds ratio = 1.89, 95% CI = 1.075–3.338, P= 0.03). This association
remained significant after adjustment for age, gender, smoking, severity of depressive symptoms at baseline and n-3
supplementation. Consistent results were obtained for individual PUFAs, including lower levels of eicosapentaenoic acid and
docosahexaenoic acid. The predictive capacity of these findings was specific to mood disorders as no associations were found for
any other psychiatric disorder. To our knowledge, our data provide the first prospective evidence that the n-6/3 PUFA ratio is
associated with an increased risk for mood disorders in young people exhibiting an UHR phenotype. These findings may have
important implications for treatment and risk stratification beyond clinical characteristics.
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INTRODUCTION
Long-chain polyunsaturated fatty acids (PUFAs) have important
physiological functions and are key regulators of cell membrane
properties. As such, they play important structural and functional
roles in the human brain and affect monoaminergic neurotrans-
mission, dendritic arborization, synapse formation, and ion
channel function.1,2 Omega-3 (n-3) PUFAs have been shown to
possess anti-inflammatory 3 and antioxidant 4 properties, while n-6
PUFAs are generally seen as pro-inflammatory, and a high n-6/3
PUFA ratio is thought to have adverse health effects.5
Epidemiological studies show that the dietary intake of n-3
PUFAs through fish consumption is inversely correlated with the
prevalence of depression,6,7 thus suggesting that n-3 PUFAs have
a protective effect. While the traditional human diet has a ratio of
n-6/3 PUFA of approximately 1:1, contemporary Western diets are
characterized by a ratio of around 15:1, reflecting deficient intake
of n-3 fatty acids and excessive intake of n-6 fatty acids.8
Importantly, adherence to a Western diet is associated with a
higher prevalence of depression.9 This has given rise to the
hypothesis that the long-term changes in dietary patterns that
have occurred in industrialized countries over the last centuries
have led to an increase in the n-6/3 PUFA ratio,5 which may be
causally linked to an increase in the incidence of mood disorders.
Indeed, case–control studies have suggested that individuals with
depression have lower levels of n-3 PUFAs and higher n-6/3 PUFA
ratios compared to healthy controls.10 Recent meta-analyses of n-3
PUFAs supplementation trials in patients with depression have
resulted in inconsistent conclusions. Some meta-analyses have
concluded that n-3 PUFA supplementation does not have a
significant benefit on depressive symptoms,11 while others have
found significant beneficial effects,12–14 which appeared to be
related to higher doses of the n-3 PUFA eicosapentaenoic acid
(EPA).12,15,16 Although lower levels of n-3 PUFAs and higher n-6/3
PUFA ratios have been reported in adults with depression, little is
known about PUFA levels in youth, nor whether abnormalities in
membrane lipid composition precede the onset of depression in
this group. This is salient because even prenatal and early
childhood diet appears to play a role in risk for mood disorders,
and as such represents a potential intervention target.17
An important mechanistic question is whether individuals with
low levels of n-3 PUFAs or an increased n-6/3 PUFA ratio are at
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elevated risk of developing mental disorders. We have recently
demonstrated that higher levels of α-linolenic acid, the ‘parent’
essential fatty acid of the n-3 family, predicted short-term
functional improvement among individuals at ultrahigh risk
(UHR) of developing psychosis who receive n-3 PUFAs
supplementation,18 while decreased levels of nervonic acid,
a monounsaturated very long-chain fatty acid involved in
myelin synthesis, predicted transition to first-episode psychosis
in the same study.19 In contrast, longitudinal studies investigating
associations of n-3 PUFAs and depressive symptoms in
general adult population samples have not reported significant
associations.20,21
To address the hypothesis that low levels of n-3 PUFAs or an
increased n-6/3 PUFA ratio precedes the onset of mood disorders
in at-risk groups, we conducted a secondary analysis of the Vienna
n-3 study, a 12-week randomized controlled trial (RCT) of n-3
PUFAs or placebo in UHR patients,22 to test whether erythrocyte
membrane levels of PUFAs predict mood disorders during a
(median) 7-year follow-up in young individuals with UHR for
psychosis.
MATERIALS AND METHODS
Study design
The present study is a secondary analysis of a double-blind RCT of n-3
PUFAs for indicated prevention of psychosis transition in individuals at
UHR for psychosis (trial registration: clinical trials.gov identifier:
NCT00396643). Details of this RCT, including the trial design, interventions,
randomization, inclusion and exclusion criteria, blinding and study
measures have been published elsewhere.22 Briefly, a 12-week intervention
with 1.2 g per day of n-3 PUFAs (700 mg EPA, 480 mg docosahexaenoic
acid (DHA)) or placebo was conducted with follow-up at 1 year and 7 years
(median) after baseline. The study was approved by the Medical University
of Vienna Ethics Committee, and written informed consent was obtained
from all participants or participants and their legal guardians for
participants aged o18 years.
Participants
Eighty-one treatment-seeking individuals were enrolled in the original
study. All participants were consecutive admissions to a specialized
psychosis detection and treatment unit at the Department of Child and
Adolescent Psychiatry, Medical University Vienna, between 2004 and 2006.
Participants were aged 13–25 years at first presentation and met criteria for
one or more of the three operationally defined and well-validated risk
factors for psychosis proposed by Yung et al.23 attenuated positive
psychotic symptoms; transient psychosis; and genetic risk plus a decrease
in functioning. The present study sample consists of 69 of the 81
individuals enrolled in the trial (85.2%; 47 female, 22 male; mean age 16.38
years, s.d. 1.83) who had information on diagnostic outcomes 7 years
(median) after study entry.
Psychometric assessments
The primary outcome measure used for this study was any occurring
diagnosis of mood disorder according to the Diagnostic and Statistical
Manual of Mental Disorders, 4th ed. (DSM-IV) criteria within the 7-year
follow-up period, ascertained in a personal interview with the participant
using the Structured Clinical Interview for DSM-IV-TR Axis I disorders (SCID-
I/P) at the longer term follow-up assessment (median 7 years after
enrollment into the study). If a participant was unavailable for an interview,
we aimed to establish psychiatric diagnoses using next of kin and/or
medical record information. The Global Assessment of Functioning (GAF)
scale was used to measure social, occupational, and psychological
functioning at baseline and follow-up. The Montgomery–Asberg Depres-
sion Rating Scale (MADRS) was used to assess depressive symptoms. Inter-
rater reliability estimates were high (intra-class correlation coefficients
40.92). Cronbach’s alpha for the MADRS in this study was 0.89. Inter-rater
reliability was maintained by using videotaped interviews every 3 months
across the initial 12 months of the RCT and before longer term follow-up.
Analysis of erythrocyte membrane PUFA composition
Erythrocyte membrane phospholipid composition closely reflects that of
neuronal membranes and provides an easily accessible indicator of brain
phospholipids.24 Erythrocytes were separated from whole blood samples
and the PUFA composition of phospholipids of the phosphatidylethano-
lamine fraction was analyzed from erythrocyte membranes. Phosphatidy-
lethanolamine was chosen because it contains higher levels of PUFAs
relative to other phospholipids. We used gas chromatography to
determine values for PUFAs and included the following into our analysis:
18:2n-6, 18:3n-6, 20:3n-6, 20:4n-6, 22:2n-6, 22:4n-6, 18:3n-3, 20:5n-3, 22:5n-
3, 22:6n-3. The detailed methods and rationale are published in previous
reports.25
Statistical analysis
We included all study participants who did not meet the case definition
(that is, being diagnosed with a mood disorder within the follow-up
period, n= 43, Table 1) as the comparison group, which thus consisted of
individuals with no psychiatric disorder, but also individuals with psychotic
disorders, anxiety disorder and/or other psychiatric disorders.
As an alternative to the conservative Kolmogorov–Smirnov test with
Lilliefors correction, normality of data was ascertained by assessing the
skewness of data distribution and the associated standard errors. Skewed
variables were log transformed, and a range of o3 was used as the cut-off
for the use of parametric tests.
Unadjusted between-group differences in demographic variables and
fatty acids (FAs) were tested with independent samples t-tests and Χ2 tests
or Fisher’s exact test for continuous and categorical variables, respectively,
and group mean values were transformed into effect size measures
(Cohen’s d) for comparison of FAs between diagnostic categories. We used
repeated measures analysis of variance (ANOVA) to examine changes in
scores between and within groups. Logistic regression was used to
calculate odds ratios (OR) and 95% confidence intervals (CIs) for mood
disorder diagnosis within the 7-year follow-up period. PUFAs (z-
transformed values) and their composite indices were used as indepen-
dent variables and ORs were calculated per s.d. increase in PUFA levels. All
regression models were fitted as unadjusted models, models adjusted for
age, gender and smoking and models adjusted for age, gender, smoking,
baseline MADRS score and n-3 PUFA/placebo group status. We conducted
sensitivity analyses excluding individuals with psychotic disorder outcome
from both case and comparison group for all tests. The Hosmer–Lemeshow
test was used to test model calibration. All tests were two-sided, a P-value
of o0.05 was considered significant. SPSS version 22 was used for all
analyses.
RESULTS
Demographics and psychometric measures
The median follow-up duration was 7.14 years (IQR= 1.13 years).
The sources of information to determine diagnostic outcome were
interviews (61 with participants, 4 with next of kin) for 94.2%
(65/69) and medical records for 5.8% (4/69) of participants. Of
these 69 participants, 26 (37.7%) received a mood disorder
diagnosis during the follow-up period (24 major depressive
disorder; 2 bipolar II disorder), 20 converted to a psychotic
disorder, 19 received an anxiety disorder and 7 a substance use
disorder diagnosis. No significant differences in any of the
demographic variables were found between participants with
and without mood disorder (Table 1). While GAF scores were not
significantly different between the two groups at the baseline
assessment, we found a significant time by group interaction
(F1.000 = 4.50, P= 0.04), indicating that GAF scores changed
differentially between individuals with and without a mood
disorder diagnosis. Post hoc tests revealed that GAF scores did
not change significantly during the follow-up period in individuals
with mood disorders (baseline 56.9 ± 11.1 vs follow-up 58.1 ± 13.2,
P= 0.62), whereas individuals with no mood disorders improved
significantly (baseline 62.2 ± 13.6 vs follow-up 71.1 ± 16.9,
Po0.001). No significant time by group interaction and no
between-group differences were found in MADRS scores at
baseline and follow-up.
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Between-group differences in PUFAs
Three n-6 PUFAs, two n-3 PUFAs, the sum of n-3 PUFAs, and the n-
6/3 PUFA ratio were differentially elevated or decreased at
baseline in patients with subsequent mood disorders relative to
the comparison group (Table 2). This effect was specific for mood
disorders; no group differences were found for psychotic
disorders, anxiety disorders or any other psychiatric disorder.
Patients with mood disorders at follow-up had lower baseline
levels of linolenic acid (18:2n-6), higher baseline levels of γ
-linolenic acid (18:3n-6) and docosadienoic acid (22:2n-6), lower
levels of EPA (20:5n-3), lower levels of DHA (22:6n-3), lower sum of
n-3 PUFAs, and a higher n-6/3 PUFA ratio. No differences were
found between patients with mood disorders at follow-up with
previous mood disorder episodes relative to patients with no
history of mood disorders (all PUFAs P40.14). Sensitivity analyses
excluding participants who converted to psychosis (n= 20)
showed that EPA (P= 0.009) and the sum of n-3 PUFAs (P= 0.04)
remained significantly lower in individuals with mood disorder
compared to individuals without mood disorder, while linolenic
acid (18:2n-6), γ-linolenic acid (18:3n-6), docosadienoic acid (22:2n-
6), DHA (22:6n-3), and the n-6/3 PUFA ratio consistently remained
at trend level. To exclude the possibility of selection bias, we also
tested for differences in PUFA concentrations between partici-
pants with and without follow-up data and found that their
membrane PUFA profiles did not differ (all PUFAs P40.277).
Regression analysis of PUFAs for mood disorder
Binary logistic regression analysis with n-6/3 PUFA ratio as the
independent variable demonstrated that a higher basal n-6/3
PUFA ratio predicted mood disorder over the 7-year follow-up
period (Table 3). The effect remained significant when we
adjusted the model for gender, age, baseline MADRS score and
n-3/placebo group status. This relationship appeared to be driven
by a lower sum of n-3 PUFAs, which was independently predictive
of mood disorder diagnosis. A series of logistic regression analyses
revealed that linolenic acid (18:2n-6), γ-linolenic acid (18:3n-6),
docosadienoic acid (22:2n-6), EPA (20:5n-3), and DHA (22:6n-3)
individually predicted mood disorders (Table 3). Sensitivity
analyses excluding participants who converted to a psychotic
disorder (n= 20) showed that EPA (20:5n-3), DHA (22:6n-3) (trend
level), and the n-6/3 PUFA ratio (trend level), remained predictive
of mood disorders and were thus consistent with our main
findings. The significant findings also persisted when the two
participants with a Bipolar II diagnosis at follow-up were excluded.
Effect modification by gender
We found a gender difference in docosapentaenoic acid (22:5n-3),
such that females had lower levels compared to males (2.09 ± 0.42
vs 2.34 ± 0.39, P= 0.01). However, gender did not affect the
relationship between any of the PUFAs and mood disorder in the
logistic regression models (all P40.48).
DISCUSSION
In the present study, we tested the hypothesis that n-6/3 PUFA
ratio is a risk biomarker26 for mood disorders and found that a
higher n-6/3 PUFA ratio in erythrocyte membranes predicts
incident mood disorders in young people exhibiting an UHR
phenotype. This predictive capacity of n-6/3 PUFA ratio was
specific for mood disorders in this cohort, that is, the n-6/3 PUFA
ratio did not influence the risk of developing any other psychiatric
disorder and persisted after adjusting our model for several
confounders, including age, gender, smoking, baseline depressive
symptoms, and n-3 supplementation. Cross-sectional studies
Table 1. Demographic characteristics
All individuals with follow-up data Mood disorder at follow-up No mood disorder at follow-up P-value
(n=69) (n=26) (n= 43)
Mean s.d. Mean s.d. Mean s.d.
Age at baseline (years) 16.3 1.8 16.3 1.7 16.4 1.8 0.879a
N % N % N %
Sex (female) 47 68.1 17 65.4 30 69.8 0.705b
Alcohol 0.577c
Less than weekly 40 58.0 16 61.5 24 55.8
1-6 drinks per week 18 25.7 5 18.5 13 30.2
Daily 11 15.7 5 18.5 6 14.0
Cannabis 0.060c
No 58 84.1 21 80.8 37 86.0
o2 g per week 7 10.0 5 18.5 2 4.7
42 g per week 4 5.7 0 0.0 4 9.3
Smoking 35 50.7 16 61.5 19 44.2 0.162b
Any illicit drug 13 18.6 5 7.1 8 11.4 0.599c
Mean s.d. Mean s.d. Mean s.d.
MADRS score baseline 18.0 8.9 20.5 8.6 16.7 8.9 0.093a
MADRS score long-term follow-up 14.4 11.0 17.2 9.8 12.9 11.5 0.164a
GAF score baseline 60.2 12.9 56.9 11.1 62.2 13.6 0.099a
GAF score long-term follow-up 66.2 16.7 58.1 13.2 71.1 16.9 0.001a
Abbreviations: GAF, Global Assessment of Functioning; MADRS, Montgomery–Asberg Depression Rating Scale. aIndependent samples t-test. bChi-Square.
cFisher’s Exact.
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suggest that people with depression have higher n-6/3 PUFA
ratios compared to healthy controls, characterized by overall lower
n-3 levels, but normal n-6 levels.10 These observations are in line
with the hypothesis that the changes in diet over the past 150
years may have caused an increase in the incidence of depression
through increased n-6/3 PUFA ratios. To the best of our
knowledge, this study is the first to test the hypothesis that
higher n-6/3 PUFA ratios posit a risk for future depression in a
longitudinal design with a long (7-year median) follow-up in at-
risk individuals.
N-6 PUFAs, n-3 PUFAs, and the balance between the two are
important to maintain physiological membrane properties.27 The
n-3 PUFA content in the lipid bilayer of mammalian cells
determines the physiological functions of the cellular membrane,
including membrane fluidity and the function of ion channels and
membrane receptors.27,28 As such, n-3 PUFAs are thought to
interact with several pathophysiological mechanisms in depres-
sion, including serotonergic neurotransmission 29 and decreased
neurogenesis.30 Additionally, depression is characterized by
oxidative stress, which preferentially impacts lipids, increasing
the turnover of, and hence the demand for, critical lipids, thus
aggravating this imbalance.31 Data from rodent studies show that
dietary restriction of DHA, for instance, appears to predominantly
affect DHA levels in the grey matter of cortical areas, the
hippocampus, and the striatum,32,33 and conversely, supplemen-
tation of DHA may have a neuroprotective effect on these brain
areas.34
A noteworthy finding is that individuals with a mood disorder
during the 7-year follow-up period had significantly lower EPA and
DHA levels at baseline, and these two n-3 PUFAs individually
Table 3. Odds ratios for mood disorder at 7 years follow-up for erythrocyte membrane phosphatidylethanolamine lipid levels at baseline in patients
with mood disorders
Unadjusted Model 1a Model 2b
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
ω -6 Fatty Acids
Linolenic acid (18:2n-6) 0.324 (0.111–0.942) 0.038 0.254 (0.078–0.827) 0.023 0.287 (0.086–0.950) 0.041
r-Linolenic acid (18:3n-6) 1.835 (1.069–3.150) 0.028 1.881 (1.083–3.268) 0.025 1.800 (1.028–3.150) 0.040
Docosadienoic acid (22:2n-6) 1.856 (1.095–3.145) 0.022 1.810 (1.051–3.117) 0.033 1.776 (1.029–3.065) 0.039
ω-3 Fatty Acids
Eicosapentaenoic acid (20:5n-3) 0.383 (0.185–0.793) 0.010 0.372 (0.178–0.781) 0.009 0.390 (0.172–0.883) 0.024
Docosahexaenoic acid (22:6n-3) 0.506 (0.276–0.928) 0.028 0.517 (0.279–0.960) 0.037 0.488 (0.261–0.913) 0.025
Sums and ratios
Sum of ω-3 fatty acids 0.453 (0.236–0.869) 0.017 0.446 (0.228–0.874) 0.019 0.436 (0.200–0.950) 0.037
ω -6 to ω-3 fatty acids ratio 1.894 (1.075–3.338) 0.027 1.843 (1.035–3.284) 0.038 1.815 (1.024–3.289) 0.041
Abbreviations: PUFAs, polyunsaturated fatty acids. aAdjusted for age, sex and smoking at baseline. bAdjusted for age, sex, smoking, MADRS score and ω -3
PUFA/placebo group status at baseline.
Table 2. Comparison of erythrocyte membrane phosphatidylethanolamine lipid levels at baseline in patients with mood disorder, psychosis, anxity
disorder or other psychiatric disorders after 7 years
Mood vs no mood
(n= 26 vs n= 43)
Psychosis vs no psychosis
(n= 20 vs n= 49)
Anxiety vs no anxiety
(n= 19 vs n= 50)
Other vs no other
(n= 11 vs n=58)
Effect size
(Cohen’s d)
P-value Effect size
(Cohen’s d)
P-value Effect size
(Cohen’s d)
P-value Effect size
(Cohen’s d)
P-value
LC ω -6 Fatty Acids
Linolenic acid (18:2n-6)a − 0.553 0.035 0.139 0.543 0.003 0.990 − 0.178 0.610
γ-Linolenic acid (18:3n-6) 0.582 0.023 − 0.172 0.509 0.260 0.346 0.161 0.603
Dihomo-γ-linolenic acid (20:3n-6) 0.299 0.229 − 0.114 0.683 − 0.127 0.645 0.264 0.458
Arachidonic acid (20:4n-6) − 0.191 0.447 − 0.316 0.213 − 0.211 0.410 − 0.275 0.371
Docosadienoic acid (22:2n-6) 0.612 0.017 − 0.213 0.420 0.015 0.954 − 0.188 0.579
Adrenic acid (22:4n-6) 0.243 0.327 − 0.242 0.344 − 0.148 0.592 − 0.014 0.965
LC ω -3 Fatty Acids
a-Linolenic acid (18:3n-3)a − 0.073 0.775 0.106 0.696 − 0.307 0.272 0.157 0.650
Eicosapentaenoic acid (20:5n-3)a − 0.729 0.003 − 0.134 0.612 − 0.467 0.077 − 0.233 0.497
Docosapentaenoic acid (22:5n-3) − 0.443 0.076 0.018 0.942 − 0.134 0.616 − 0.058 0.877
Docosahexaenoic acid (22:6n-3) − 0.618 0.010 − 0.092 0.749 − 0.486 0.090 − 0.625 0.087
Sums and Ratios
Sum of LC ω-6 fatty acidsb − 0.199 0.413 − 0.237 0.349 − 0.149 0.565 − 0.235 0.541
Sum of LC ω-3 fatty acidsb − 0.699 0.004 − 0.069 0.911 − 0.436 0.111 − 0.472 0.197
LC ω -6 to LC ω-3 fatty acids ratio 0.610 0.012 0.008 0.975 0.278 0.335 0.283 0.435
aLog transformed. bSum comprises long-chain fatty acids ⩾20 carbon atoms.
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predicted mood disorder in our logistic regression models. This
finding is in line with evidence from studies showing that EPA and
DHA in particular are decreased in patients with depression.10
DHA is highly abundant in the human brain and constitutes up to
40% of the total brain FAs, while EPA accounts only for 1%.35 EPA
and DHA are believed to be the main active ingredients in n-3
PUFA supplementation, and importantly, meta-analysis suggests a
dose-response relationship between EPA content and clinical
efficacy and only supplements with a high EPA content appear to
be effective in patients with depression.12,16
Converging evidence from recent proteomic and transcriptomic
studies suggest a modulatory effect of n-3 PUFAs on immune
function, including downregulation of transcripts for IL-1beta, IL-6
and TNF-α, and the NFkappaB pathway.36,37 Consequently, low
levels of n-3 PUFAs are thought to be associated with a pro-
inflammatory phenotype.3 This view is supported by population-
based studies demonstrating that a high n-6/3 PUFA ratio is
associated with increased pro-inflammatory cytokines.38 Data
from pre-clinical studies show that a high n-6/3 PUFA ratio
predisposes mice to an excessive immune reaction when
confronted with a lipopolysaccharide immune challenge.39 More-
over, transgenic mice that express n-3 PUFA desaturase, an
enzyme that catalyses the conversion from n-6 to n-3 PUFAs that
is not naturally expressed in mammalian cells, produce less pro-
inflammatory cytokines IL-1β, IL-6 and TNF-α in response to a 24-h
lipopolysaccharide challenge, show a higher proportion of more
neuroprotective MHC II-positive microglial cells, and are protected
from spatial memory deficits.40 One clinical study demonstrated
that a high n-6/3 PUFA ratio markedly increased production of IL-6
and TNF-α and patients with depressive symptoms.41 The
relevance of these findings is supported by a recent study
demonstrating that only patients with depression and high levels
of several pro-inflammatory cytokines respond to n-3 PUFA
supplementation, while those patients with low inflammation do
not respond.42 Collectively, these data suggest that the high n-6/3
PUFA ratio and the low levels of EPA and DHA found in our study
may exert their risk for depression partially through immune
mechanisms.
Mood disorders were the most common psychiatric diagnosis at
follow-up in the Vienna omega-3 study43 and in other samples of
individuals at-risk for psychosis,44 affecting up to 42% of
individuals who present with an UHR phenotype. Recent research
on the frequency of the UHR phenotype in the general population
also demonstrated a prevalence of 1.3% and 9.9% for any UHR
symptom.45 Furthermore, based on cumulative findings from
long-term follow-up studies, the UHR concept has become more
explicitly trans-diagnostic or pluripotent.43 This highlights the
importance of studying UHR individuals in regard to mood
disorder outcomes. Unlike general population samples,20,21 UHR
individuals represent a viable target group for risk stratification
using risk biomarkers,26 which adds clinical relevance to our
findings. However, the n-3 PUFA intervention raises the question
as to whether it had an influence on psychiatric outcomes or if it
altered the relationship between membrane PUFAs and psycho-
pathology. We have previously shown that the n-3 PUFA
intervention, while effective in preventing psychosis, did not
reduce the risk for mood disorders or MADRS scores.43 Patients
who received n-3 PUFA and patients who received placebo did
not differ in their PUFA profiles at baseline.22 Finally, adjusting our
regression models for treatment group did not change the main
result. We thus believe that the 12-week intervention does not
have implications for the interpretation of the findings of the
present study.
Several limitations need to be considered when interpreting the
findings of this study. Most importantly, the participants in this
study were recruited at a specialized service for early psychosis
according to UHR criteria, and thus represent a specific group of
young help-seeking individuals. The results of this study might not
generalize beyond this setting. Secondly, the relatively small
sample size increases the risk of missing smaller effects in some of
the variables and warrants replication of our findings. Thirdly, we
did not measure dietary intake of n-3 PUFA during the trial and we
thus cannot rule out the possibility that the differences in
membrane PUFA composition at baseline in participants who later
developed a mood disorder were caused by dietary intake.
Strengths of the study include the long follow-up period of 7 years,
the use of standardized assessment instruments, the robustness of
the findings in the sensitivity analysis, and finally the consecutive
sample of UHR individuals allowed a comparison group that
consisted of individuals with a variety of psychiatric diagnoses and
thus showed that our findings are specific for mood disorders. In
addition, the finding of reduced EPA and DHA levels in individuals
who later developed a mood disorder adds face and biological
validity, as both of these PUFAs have been implicated in the
pathophysiology of depression. Our findings are clinically relevant
since mood disorders are the most frequent psychiatric condition
observed in UHR patients. Together with meta-analytic evidence
showing the efficacy of supplementation with EPA-predominant
formulations in depression, our findings provide a rationale for
longer term n-3 supplementation in UHR individuals.
In conclusion, our results highlight the importance of lipid
biology for the identification of risk biomarkers among individuals
with UHR states by demonstrating a longitudinal association
between membrane PUFA levels and mood disorders 7 years later.
These findings support the hypothesis that higher levels of n-6
PUFAs and lower levels of n-3 PUFAs, possibly due to long-term
changes in dietary intake or differential usage, pose a risk for
depression. In the context of young people at risk for mental
disorders, these findings may have important implications for risk
stratification beyond clinical characteristics.
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